GENETIC AND BIOCHEMICAL ANALYSIS OF ISOLEUCINE-VALINE MUTANTS OF YEAST¹

S. N. KAKAR AND R. P. WAGNER

Genetics Foundation, University of Texas, Austin

Received July 1, 1963

 \mathbf{I}^{N} the organisms so far investigated the biosynthesis of valine and isoleucine seems always to proceed from pyruvic acid by a series of four steps to the amino acids. The pathway shown in Figure 1 is supported by the results of a

FIGURE 1.—The biosynthetic pathway leading to isoleucine and valine. $AL = \alpha$ -acetolactate, AHB = α -aceto- α -hydroxybutyrate, DHV = α , β -dihydroxyisovalerate, DHI = α , β -dihydroxy- β methylvalerate, $KV = \alpha$ -ketoisovalerate, $KI = \alpha$ -keto- β -methylvalerate.

number of workers using yeast as the experimental organism, (STRASSMAN, THOMAS and WEINHOUSE 1955; STRASSMAN, THOMAS, LOCKE and WEINHOUSE 1956; STRASSMAN, SHATTON, CORSEY and WEINHOUSE 1958; STRASSMAN, SHAT-TON and WEINHOUSE 1960; LEWIS and WEINHOUSE 1958; WIXOM, SHATTON and STRASSMAN 1960). The present study was undertaken to analyze the basic biochemical characteristics of a group of mutants of the yeast, Saccharomyces cere*visiae*, requiring both isoleucine and valine, and to correlate these characteristics with such genetic information as could be obtained.

¹ This work was supported by a Robert Welch Foundation Fellowship to the senior author, by Research Grant RG 6492 from the National Institutes of Health, Public Health Service, and by a Public Health Service research career award, GM-K6-18,383 to the junior author.

Genetics 49: 213-222 February 1964.

214 S. **N. KAKAR AND R. P. WAGNER**

MATERIALS AND METHODS

The basic media used and the general techniques employed for genetic analysis have been described previously by KAKAR (1963). The minimal medium referred to in the present work contained glucose, mineral salts and vitamins (ROMAN 1956), but no amino acids, purines or pyrimidines, unless otherwise stated. The "complete" medium contained in addition DL-isoleucine (60 μ g per ml), DL-valine (60 μ g per ml), L-histidine (10 μ g per ml) and L-tryptophan (10 μ g per mil). Solid medium contained 1.5 percent Bacto-agar.

The diploid cells were sporulated for dissection as described by FOGEL and HURST **(1963).**

The isoleucine-valine requiring mutants were isolated from haploid strains 7029C, A429C and A468A obtained from the yeast stock collection at the University of Washington, Seattle. Strain 702% is mating type *a* and requires tryptophan for growth while A429C and A468A are mating type α and require histidine.

Mutants were obtained by inoculating approximately 400 cells of the parent strains on the surface of plates containing the complete medium described above, and irradiating with a dose of ultraviolet light sufficient to produce approximately 50 percent survivors. After three to four days incubation at 30°C the colonies were tested for an isoleucine and valine requirement by the replica plating method with a velvet stamp. A total of 19 isoleucine-valine requiring mutants was obtained, 11 from 7029C, four from A429C and four from A468A. In addition seven mutants were obtained which required isoleucine only. Two more isoleucine-valine mutants, EU-38 and Nr-211-laM were obtained from DR. R. K. MORTIMER of the University of California, Berkeley, and DR. W. LASKOWSKY of the Freie Universitat, Berlin, respectively. Both of these mutants are of mating type *a.*

Complementation between the various isoleucine and isoleucine-valine mutants was studied by crossing mutant cells of opposite mating type on yeast extract-peptone medium containing 1 percent yeast extract, 2 percent bactopeptone, 2 percent glucose and 1.5 percent agar. After 18 to 24 hours incubation to permit mating to take place, the diploid zygotes were tested on isoleucine free, valine free and isoleucine-valine free media. Those diploids with complementing genes grew on the test media.

To determine whether mutation to a simultaneous requirement for isoleucine and valine involved the mutation of one or more than one gene, the mutant strains were crossed to one of the parent wild-type strains of opposite mating type. The resulting diploids were then analyzed after sporulation. Also, tests for allelism between the mutant genes of various complementation groups were made by crossing representative mutants from each of the groups and analyzing the resulting diploids.

For enzyme studies a small inoculum was grown on a shaker in 5 ml of liquid yeast extractpeptone medium for two days. The cells were washed by centrifugation and suspended in 2 ml of water. Two flasks, each containing 500 ml **of** complete liquid medium, were then inoculated with 1 ml of the yeast suspension, and incubated 20 to 24 hours at 30° C with continuous shaking. One mutant, M-22, grew very slowly on this medium and it was necessary to grow it four to five days to obtain a sufficient number of cells. The cells were harvested by centrifugation, and the medium analyzed for the accumulation of carbinols, dihydroxy acids and keto acids by the methods described by WAGNER and BERGOUIST (1960).

The harvested cells were washed twice in distilled water and suspended in cold 0.1 M phosphate buffer at pH 7.5. They were then broken in a press by the method and apparatus described by EATON (1962). The broken cells in suspension were centrifuged 20 min at 56,000 \times g or 70,000 \times g in a Spinco Model L centrifuge. The pellets were discarded and the supernatants used for enzyme analyses. Protein concentrations of the supernatants were determined by the method of LOWRY, ROSENBROUGH, **FARR** and RANDALL (1951). Enzyme assays with the supernatants were carried out as follows.

Threonine deaminase activity was assayed by adding 20 micromoles of *L*-threonine to supernatant extract containing 1 to 2 mg of protein in sufficient 0.1 M phosphate buffer at pH 8.0 to make 2.0 ml, and 40 μ g of pyridoxal phosphate. This reaction mixture was incubated at 37°C for 10, 20 and 30 minutes, and the reaction stopped by the addition of 0.5 ml 10 percent trichloracetic acid. The α -ketobutyric acid produced was determined by the method of FRIEDMANN and HAUGEN (1943).

The condensing enzyme was assayed in a mixture containing 500 μ g sodium pyruvate, 100 μ g thiamine pyrophosphate, 10 μ moles MgSO₄, 1 to 2 mg of protein and sufficient 0.1 μ phosphate buffer at **p9** *6.25* to make a total volume *of* 4.5 ml. The reaction mix-ture was incubated 30 min at 37°C and stopped by adding 0.5 ml of 6_N sulphuric acid. After the addition of the acid the tubes were incubated 30 min at 60° to decarboxylate the remaining α -acetolactate. The carbinol remaining was then determined quantitatively by the WESTERFELD (1945) test.

Reductoisomerase activity was measured by determining the rate of oxidation **of** NADPH, (reduced nicotinamide-adenine dinucleotide phosphate) spectrophotometrically in the presence of α -aceto- α -hydroxybutyrate or α -acetolactate. The assay mixture contained 100 μ moles of one of the a-aceto acid substrates, 10 μ moles of NADPH₂, 100 μ moles of MgSO₄, and about 0.1 mg of extract protein in sufficient 0.1 M phosphate buffer at pH 7.5 to make a total volume *of* 0.9 ml. In practice the cuvette containing all **of** the reactants save the NADPH, was incubated first for 30 min at 37°C and then the NADPH, added and the change in optical density recorded at 340 **mp** with a Beckman or Gary recording spectrophotometer.

The determination of dehydrase enzyme activity was accomplished by incubating, for 30 min at 37°C, a mixture containing 20 μ moles of α,β -dihydroxy- β -methylvalerate or α,β -dihydroxyisovalerate, 20 μ moles MgSO₄, and 1 to 2 mg of extract protein in 0.1 M Tris buffer at pH 7.4 to make 2.0 ml. The reaction was stopped by the addition of 0.5 ml of 10 percent trichloracetic acid. The mixture was then assayed for a-keto acids by the method of FRIEDMANN and HAUGEN (1943).

Transaminase enzyme activity was determined chromatographically. A mixture containing 40 μ moles of α -keto- β -methylvalerate or α -ketoisovalerate, 40 μ moles of donor amino acid, 20 μ g of pyridoxal phosphate, 3 to 4 mg of extract protein and sufficient 0.1 M phosphate buffer at pH 8.0 to make 1.5 ml was incubated 3 hr at 37°C. The reaction was stopped by heating the incubated mixture in boiling water for 5 minutes. After cooling, 0.5 ml of glacial acetic acid was added and the resulting precipitate removed by centrifugation. A small sample **of** the supernatant was then applied to Whatman No. 1 filter paper and ascending chromatography carried out with a solvent system consisting of n-butanol, glacial acetic acid and water in volume proportions of **40:** IO: 50. Isoleucine or valine were determined qualitatively by comparison with known standards.

The substrates α -acetolactate and α -aceto- α -hydroxybutyrate were prepared in this laboratory using the methods described by KRAMPITZ (1948) and RADHAKRISHNAN and SNEU (1960). The α , β -dihydroxy acids were prepared by the method of SJOLANDER, FOLKERS, ADELBERG and TATUM (1954). NADPH₂, pyridoxal phosphate and α -ketoisovalerate were obtained from the Sigma Chemical Company.

RESULTS

Genetic analysis: If the requirement for both isoleucine and valine is the result of a single gene mutation, then among the products of meiosis of a mutant \times nonmutant cross, the two requirements would be expected to segregate together. Otherwise, some **of** the segregants would require either isoleucine or valine alone. Mutants M-12, M-22, M-3, M-4, six mutants from Group I11 (see complementation results below) and six mutants from Group IV have been analyzed in this way. From ten to 40 asci were dissected in each case. In general, poor viability **of** the spores has been a problem thus producing a very low proportion **of** four spored asci. The extreme cases have been the crosses involving EU-38 (25 asci were dissected) and M-28 (ten asci were dissected) where only 13 and four spores grew respectively. However, in all the cases, among the segregants that did grow, the two requirements always segregated together.

The results of the crosses are given in Table 1. From them it can be tentatively concluded that the double requirement for isoleucine and valine arises as the result of a single gene mutation.

Crosses were also made to test for allelism and linkage among the mutants. Isoleucine-valine independent segregants were readily obtained from crosses involving mutants of the following type: Group I \times Group III, Group I \times IV, Group II \times Group III, Group II \times Group IV and Group III \times Group IV. The results suggested that the Group I11 and IV mutant genes are not linked to one another nor to the Group I and I1 mutants. **A** cross between the Group I mutant M-12 and the Group I1 mutant M-22 gave results indicating close linkage, however. From this cross two isoleucine-valine independent spores were found from among 40 asci analyzed. Thus $M-12$ and $M-22$ appear to be approximately 2.5 units apart.

Complementation tests: Table 2 presents the results from the complementation tests. It is clear from these data that most of the mutants fall into two main complementation groups: Group I11 with ten, and Group IV with eight mutants. Mutants M-12 and M-22 are designated as Group I and II respectively, since they complement with all others as well as one another. The isoleucine mutants do not complement with one another, but do complement with all the isoleucinevaline mutants, and are hence designated as Group V.

Cross	Number of asci dissected	Number of spores growing	Number of $I+V+$ spores	Number of $I-V^-$ spores	Number of 4-spored asci $(2.2$ segregation)
Group I					
$M-12\times WT$	37	119	73	46	14
Group II					
$M-22\times WT$	26	43	35	8	1
Group III					
M -7 \times WT	6	17	10	7	2
M -13 \times WT	11	30	20	10	0
M -14 \times WT	40	90	62	28	4
M -16 \times WT	24	62	38	24	5
M -18 \times WT	7	23	14	9	2
$\mathrm{M}\text{-}28\times\mathrm{WT}$	10	4	$\overline{4}$	θ	$\bf{0}$
Group IV					
$\mathrm{M}\textrm{-}1\times\mathrm{WT}$	16	42	32	10	θ
$\mathrm{M-2}\times\mathrm{WT}$	10	27	17	10 ¹	0
M -11 \times WT	26	63	40	23	6
M -15 \times WT	16	45	33	12	$\mathbf{2}$
EU-38 \times WT	25	13	10	3	$\bf{0}$
$Nr-211-1aM \times WT$	6	22	11	11	5
Others					
$\mathrm{M}{\text -}3\times \mathrm{WT}$	16	28	18	10	1
$\text{M-4} \times \text{WT}$	16	51	30	21	5

TABLE 1

Segregation for isoleucine and valine requirement

TABLE 2

Complementation between various isoleucine and isoleucine-valine mutants

(+) and (-) represent whether or not the diploids grow on isoleucine-free (is-) or valime-free (v -) media.
(s) represents that the diploids grew slowly on the plates.

ISOLEUCINE-VALINE YEAST MUTANTS

Enzymatic activities: Enzymatic activities for the centrifuged crude extracts of the various strains are given in Table **3.** All the isoleucine-valine mutants were tested as well as the three parent strains. Where a range of values is given in the table it indicates the range found for a number of assays for a single mutant which is designated in the table, or for the entire group of mutants.

When compared to the wild-type strains, it is seen that mutants M-12 and M-22 showed comparable ranges of enzyme activity except for reductoisomerase activity in the presence of $\overline{M}g^{++}$. This is true for both substrates, α -aceto- α hydroxybutyrate and *a*-acetolactate. A significant point, furthermore, is the fact that the activity was found to be the same for the mutants in the presence and absence of added Mg⁺⁺. When, however, Mg⁺⁺ is omitted from the assay mixtures of the wild types or the other mutant strains a considerable depression of activity is noted. The Mg+ + dependence **of** the reductoisomerases **of** *Escherichia coli, Salmonella typhimurium* and *Neurospora crassa* has been well established by the work of RADHAKRISHNAN, WAGNER and SNELL (1960) and ARM-STRONG and WAGNER (1961). The activity remaining in the absence of Mg⁺⁺ in crude extracts such as exhibited here in yeast has been called the "residual activity" (ARMSTRONG and WAGNER 1961) and presumably reflects the activity of another enzyme which converts the α -aceto acids to some unknown compound in the presence of NADPH₂ rather than to the α , β -dihydroxy acids.

The low threonine deaminase activity of M-22 may be the result of prolonged growth. It is this mutant which must be grown for several days to obtain sufficient cells for preparing enzyme extracts. We have found that if we allowed the isoleucine-valine independent strain, 7029C, to grow on the shaker for four to five days, the threonine deaminase activity was reduced to the level observed for M-22.

The Group **I11** mutants are deficient in dehydrase activity as determined by the ability of their extracts to convert α , β -dihydroxy- β -methylvalerate to the

TABLE 3 *Specific activity of crude extracts of various yeast strains*

(@moles product formed/mg protein/hour)

a-keto acid precursor of isoleucine. Two of the mutants, **M-14** and **M-4,** were also tested for activity with α , β -dihydroxyisovalerate, the precursor of valine, and found to be correspondingly inactive with this substrate too.

It can be seen from Table *3* that the Group *N* mutants have the wild-type range of activity for all enzymes. The reason for their requirement for isoleucine and valine is difficult to understand, but it should be pointed out that in this respect they are quite similar to the Group I1 isoleucine-valine mutants of *Neurospora crassa* described by WAGNER, KIRITANI and BERGQUIST **(1962).**

The isoleucine mutants **M-6** and **M-27** are both deficient in threonine deaminase activity. The other isoleucine mutants were not tested.

Crude extracts **of** *Neurospora crassa* are active in the transamination of **a**ketoisovalerate and @-keto-P-methylvalerate in the presence **of** L-phenylalanine (WAGNER and IFLAND **1956;** SEECOF and WAGNER **1959).** L-phenylalanine is, however, a poor donor for these keto acids in yeast, and its conversion to phenylpyruvate cannot be measured spectrophotometrically in the wild-type strain **7029C** using the method of CAMMARATA andCOHEN **1951.** Table **4** presents the results of testing 17 different amino acids as donors for the α -keto analogues of isoleucine and valine by the method described above, and using chromatography to identify the end products. The three parent strains and all **of** the isoleucinevaline mutants were tested and all gave the same pattern of results. Leucine seems to be the best donor for both keto acids while valine transaminates readily with α -keto- β -methylvalerate and isoleucine with α -ketoisovalerate. None of the mutants tested gave any indication **of** being transaminase deficient by the relatively crude assay procedure used here.

Donor amino acid	With α -ketoisovalerate	With α -keto- β -methylvalerate		
ornithine	w	w		
leucine	S			
alanine	M	w		
norvaline		м		
methionine	*	м		
valine	i.	S		
isoleucine	S	\cdot .		
phenylalanine	w	w		
norleucine	м			
glutamate	м	м		
lysine				
α -aminobutyrate				
glycine				
tyrosine				
tryptophan				
aspartic acid				
threonine				

TABLE 4 *Transaminase activity of the crude extracts of yeast*

 $S =$ strong spots, $M =$ medium spots, $W =$ weak spots.

^{*} Valine or isoleucine spots were not distinguishable from the donor amino acid spots in the solvent system used.

UMBARGER and BROWN (1958a) have shown that the threonine deaminase of *Escherichia coli* is inhibited by isoleucine, and its condensing enzyme by valine. In Neurospora and Salmonella, however, evidence has been presented that such feedback inhibition is not found for the condensing enzymes or the enzymes which follow it in the isoleucine-valine pathway. It was, therefore, of interest to determine whether isoleucine or valine had any effect on these enzymatic activities in yeast (RADHAKRISHNAN and SNELL 1960; ARMSTRONG, GORDON and WAGNER 1963). The results given in Table *5* show that the activity of threonine deaminase was completely inhibited by the addition of isoleucine to the assay mixture. No effect on the other enzymes was noted with this amino acid or valine.

DISCUSSION

It should be noted that all the enzyme activity analyses reported were done with crude extracts after centrifugation of broken cells. Therefore, when an extract is found to be deficient in an enzyme, it may not be for the reason that the enzyme is missing, but because it is inhibited by some other substance or substances present in the crude extract of the mutant, but not the wild type, in sufficient concentration to cause complete inhibition. This should be borne in mind in the following discussion.

The isoleucine-valine mutants described here may be assigned to four complementation groups. However, on the basis of their enzyme activities they may be assigned to only three groups since $M-12$ (Group I) and $M-22$ (Group II) both appear to be deficient in the reductoisomerase. The fact that these two strains, deficient in the same enzyme, complement readily in diploids is of some interest. Furthermore, the evidence is that they have mutations at separate loci, although this is still inconclusive, since it is based on finding two prototrophs from among 40 asci examined. They are both comparable to the Group I mutants of *Neurospora crassa* (WAGNER, KIRITANI and BERGQUIST 1962) and the *ilvaA* mutants of *Salmonella typhimurium* (WAGNER and BERGOUIST 1960).

Additions into the assay system	Enzymes and substrates								
	Threonine deaminase with L-threonine	Condensing enzyme with pyruvate	Reducto- isomerase with α -aceto- α - hydroxy- butyrate	Dehydrase with		Transaminase with			
				α , β -dihydroxy- valerate	α , β -dihydroxy- β -methyl- valerate	α -keto isovalerate*	α -keto- β - methyl- valerate*		
None	6.8	1.8	3.4	0.98	1.3				
0.01 _M isoleucine	Ω	2.0	3.3	1.04	1.2				
$0.01M$ valine	8.0	1.8	3.4	0.87	0.87				
0.01 _M glycine 0.01 M isoleucine	6.4	1.7	3.9	1.1	1.1				
$0.01M$ valine	0	1.95	3.6	0.87	1.04				

TABLE 5

Effect of isoleucine and valine on the activity of the various isoleucine-valine enzymes in crude extracts of strain 7029C

* With L-leucine as donor.

The Group I11 mutants are comparable to the Group I11 mutants of *Neurospora crassa* since they too show a deficiency of dehydrase activity. Similar deficient dehydrase mutants have also been found in Salmonella (WAGNER and BERGQUIST 1960) and *Escherichia coli* (MYERS and ADELBERG 1954).

The data are quite clear in showing that the crude supernatant extracts of the Group IV mutants have all the enzyme activities. In this characteristic they are quite similar to the Group I1 isoleucine-valine mutants of Neurospora (WAG-NER, KIRITANI and BERGQUIST 1962). Recently WAGNER and BERGQUIST (1963) have presented evidence that valine and isoleucine are synthesized from pyruvate in a particulate fraction associated with the mitochondria in Neurospora. Wild-type strains have active particles, but the Group I1 Neurospora mutants do not. Unpublished results from this laboratory indicate that these mutants have particles which are unable to convert the dihydroxy acids to the amino acids although they do have active dehydrase in the supernatant. The suggestion has been made that the isoleucine-valine system is organized in Neurospora and the Group I1 mutants have a disorganization of this system. The Group IV mutants of yeast may be similar in this respect.

In Neurospora and Salmonella the loci controlling the production of the reductoisomerase and the dehydrase are closely linked (WAGNER, KIRITANI and BERG-QUIST 1962; GLANVILLE and DEMEREC 1960). This does not appear to be true in yeast, since the Group I and I1 mutants recombine readily with the Group I11 mutants to produce isoleucine-valine independent prototrophs.

course of these investigations. We wish to acknowledge the technical assistance of MRS. M. L. GORDON **PARRISH** during the

SUMMARY

Twenty-one mutants of *Saccharomyces cereuisiae* requiring isoleucine plus valine have been partially characterized genetically and biochemically. They fall into four complementing groups with linkage indicated between only two of the groups. Enzymatic analysis reveals that two mutants which complement readily are both deficient in the reductoisomerase enzyme. A third group designated as complementation Group I11 has all of its members deficient in the dihydroxy acid dehydrase, while the Group IV noncomplementing mutants show no deficiency in any of their enzymes required for isoleucine-valine synthesis.

LITERATURE CITED

ARMSTRONG, F. B., and R. P. WAGNER, 1961 Biosynthesis of valine and isoleucine. IV. α -hy- $\overline{}$ droxy-p-keto acid reducto-isomerase of Salmonella. J. Biol. Chem. **236** : 2027-2032. 1962 Mutants **of** Salmonella deficient in reductoisomerase. Genetics **⁴⁷**: 1582-1593.

ARMSTRONG, F. B., M. L. GORDON, and R. P. WAGNER, 1963 Biosynthesis of valine and isoleucine.

VI. Enzyme repression in Salmonella. Proc. Natl. Acad. Sci. U.S. **49:** 322-329.

- CAMMARATA, P. S., and P. O. COHEN, 1951 Spectrophotometric measurement of transamination reactions. J. Biol. Chem. **193:** 45-52.
- EATON, N. R., 1962 New press for disruption of microorganisms. J. Bacteriol. 83: 1359-1360.

FOGEL, S., and D. D. HURST, 1963 Coincidence relations between gene conversion and mitotic recombination in Saccharomyces. Genetics **⁴⁸**: 321-328.

FRIEDMANN, T. E., and G. E. HAUGEN, 1943 Pyruvic acid. II. The determination of keto acids in blood and urine. J. Biol. Chem. **147:** 415-442.

- GLANVILLE, E. V., and M. DEMEREC, 1960 Threonine, isoleucine and isoleucine-valine mutants of *Salmonella typhimurium.* Genetics **45:** 1359-1374.
- KAKAR, S. N., 1963 Allelic recombination and its relation to recombination of outside markers in yeast. Genetics *43:* 957-966.
- KRAMPITZ, L. O., 1948 Synthesis of a-acetolactic acid. Arch. Biochem. **17:** 81-85.
- LEWIS, K. F., and S. WEINHOUSE, 1958 Studies in valine biosynthesis. II. α -acetolactate formation in microorganisms. J. Am. Chem. Soc. **80:** 4913-4915.
- LOWRY, O., N. J. ROSEBROUGH, A. L. FARR, and R. J. RANDALL, 1951 Protein measurement with the Folin phenol reagent. J. Biol. Chem. **193:** 265-275.
- MYERS, J. W., and E. A. ADELBERG, 1954 The biosynthesis of isoleucine and valine. I. Enzymatic transformation of the dihydroxy acid precursors to the keto acid precursors. Proc. Natl. Acad. Sci. U.S. 40: 493-500.
- RADHAKRISHNAN, A. N., and E. E. SNELL, 1960 Biosynthesis of valine and isoleucine. II. Formation of a-acetolactate and a-aceto-a-hydroxybutyrate in *Neurospora crassa* and *Escherichia* $coli$. J. Biol. Chem. **235:** 2316-2321.
- RADHAKRISHNAN, A. N., R. P. WAGNER, and E. E. SNELL, 1960 Biosynthesis of valine and isoleucine. III. α -keto- β -hydroxy acid reductase and α -hydroxy- β -keto acid reductoisomerase. J. Biol. Chem. 235: 2322-2331.
- ROMAN, H. L., 1956 A system selective for mutants affecting the synthesis of adenine in yeast. Compt. Rend. Trav. Lab. Carlsberg, Ser. Psysiol. **26:** 299-314.
- RUDMAN, D., and A. MEISTER, 1953 Transamination in *Escherichia coli*. J. Biol. Chem. 200: 591-604..
- SEECOF, R. L., and R. P. WAGNER, 1959 Transaminase activity in *Neurospora crassa*. I. Purification and substrate specificity of a phenylpyruvate transaminase. J. Bid. Chem. **234:** 2689L2693.
- SJOLANDER, J. R., K. FOLKERS, E. A. ADELBERG, and E. L. TATUM, 1954 α, β -dihydroxyisovaleric acid and **a,P-dihydroxy-P-methyl-valeric** acid, precursors of valine and isoleucine. J. Amer. 'Chem. Soc. **76:** 1085-1087.
- STRASSMAN, M., A. J. THOMAS, and S. WEINHOUSE, 1955 The biosynthesis of valine. J. Am. Chem. Soc. **77:** 1261-1265.
- STRASSMAN, M., J. B. SHATTON, and **S.** WEINHOUSE, 1960 Conversion of a-acetolactic acid to the valine precursor α , β -dihydroxyisovaleric acid. J. Biol. Chem. **235 :** 700–705.
- STRASSMAN, **M.,** A. J. THOMAS, L. A. LOCKE, and S. WEINHOUSE, 1956 Biosynthesis of isoleucine. J. Am. Chem. Soc. **78:** 228-233.
- STRASSMAN, M., J. B. SHATTON, M. E. CORSEY, and S. WEINHOUSE, 1958 Enzyme studies on the biosynthesis **of** valine in yeast. J. Am. Chem. Soc. *80:* 1771-1772.
- UMBARGER, E.E., and B. BROWN, 1958a Isoleucine and valine metabolism in *Escherichia* coli. VII. A negative feedback mechanism controlling isoleucine biosynthesis. J. Biol. Chem. **233:** 415-420. - 1958b Isoleucine and valine metabolism in *Escherichia coli.* VIII. The formation of acetolactate. J. Biol. Chem. 233: 1156-1160.
- WAGNER, R. P., and P. W. IFLAND, 1956 Biochemical and physiological studies on a strain of *Neurospora crassa* inhibited by threonine. Camp. Rend. Lab. Trav. Carlsberg, Ser. Physiol. **26:** 381-406.
- WAGNER, R. P., and A. BERGQUIST, 1960 Nature of the genetic blocks in the isoleucine-valine mutants of Salmonella. Genetics 45: 1375-1386. - 1963 Synthesis of valine and isoleucine in the presence **of** a particulate cell fraction of Neurospora. Proc. Natl. Acad. Sci. U.S. **49: 892-897.**
- WAGNER, R. P., K. KIRITANI, and A. BERGQUIST, 1962 Gene-enzyme relationship in isoleucinevaline biosynthesis. **pp.** 346-363. *The Molecular Basis of Neoplasia.* University of Texas Press, Austin.
- WESTERFELD, W. W., 1945 A colorimetric determination of blood acetoin. J. Biol. Chem. **161** : 495-502.
- WIXOM, R. L., J. B. SHATTON, and M. STRASSMAN, 1960 Studies on a dehydrase in valine biosynthesis in yeast. J. Biol. Chem. **235:** 128-131.